Tower Research Capital (TRC)’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $311K | Buy |
9,568
+9,276
| +3,177% | +$298K | 0.01% | 1282 |
|
|
2025
Q4 | $10.3K | Sell |
292
-4,979
| -94% | -$176K | ﹤0.01% | 3805 |
|
|
2025
Q3 | $139K | Sell |
5,271
-1,703
| -24% | -$50.8K | ﹤0.01% | 1760 |
|
|
2025
Q2 | $185K | Buy |
6,974
+5,263
| +308% | +$139K | 0.01% | 1850 |
|
|
2025
Q1 | $41.3K | Sell |
1,711
-12,212
| -88% | -$386K | ﹤0.01% | 2355 |
|
|
2024
Q4 | $560K | Buy |
13,923
+4,433
| +47% | +$253K | 0.01% | 984 |
|
|
2024
Q3 | $601K | Sell |
9,490
-11,022
| -54% | -$647K | 0.02% | 756 |
|
|
2024
Q2 | $1.09M | Buy |
20,512
+19,156
| +1,413% | +$1.26M | 0.02% | 716 |
|
|
2024
Q1 | $111K | Sell |
1,356
-17,535
| -93% | -$780K | ﹤0.01% | 1772 |
|
|
2023
Q4 | $352K | Buy |
18,891
+10,820
| +134% | +$142K | ﹤0.01% | 1660 |
|
|
2023
Q3 | $89.3K | Buy |
8,071
+5,248
| +186% | +$75.1K | ﹤0.01% | 2063 |
|
|
2023
Q2 | $45.8K | Sell |
2,823
-10,150
| -78% | -$213K | ﹤0.01% | 2655 |
|
|
2023
Q1 | $216K | Buy |
12,973
+9,391
| +262% | +$97K | 0.01% | 1331 |
|
|
2022
Q4 | $34K | Buy |
3,582
+2,934
| +453% | +$13.1K | ﹤0.01% | 2646 |
|
|
2022
Q3 | $2K | Buy |
648
+644
| +16,100% | +$2.11K | ﹤0.01% | 5621 |
|
|
2022
Q2 | $0 | Sell |
4
-27,749
| -100% | -$68.7K | ﹤0.01% | 6550 |
|
|
2022
Q1 | $83K | Sell |
27,753
-32,001
| -54% | -$115K | ﹤0.01% | 2356 |
|
|
2021
Q4 | $275K | Buy |
59,754
+44,926
| +303% | +$252K | ﹤0.01% | 1533 |
|
|
2021
Q3 | $94K | Buy |
14,828
+10,150
| +217% | +$62.7K | ﹤0.01% | 2459 |
|
|
2021
Q2 | $28K | Sell |
4,678
-2,148
| -31% | -$12.8K | ﹤0.01% | 3576 |
|
|
2021
Q1 | $43K | Sell |
6,826
-4,106
| -38% | -$28.9K | ﹤0.01% | 3258 |
|
|
2020
Q4 | $61K | Buy |
10,932
+684
| +7% | +$4.14K | ﹤0.01% | 2905 |
|
|
2020
Q3 | $60K | Sell |
10,248
-10,220
| -50% | -$70.4K | ﹤0.01% | 3463 |
|
|
2020
Q2 | $148K | Buy |
20,468
+20,368
| +20,368% | +$135K | 0.01% | 2091 |
|
|
2020
Q1 | $0 | Sell |
100
-3,111
| -97% | -$19.1K | ﹤0.01% | 3956 |
|
|
2019
Q4 | $26K | Sell |
3,211
-4,790
| -60% | -$34.9K | ﹤0.01% | 1766 |
|
|
2019
Q3 | $55K | Buy |
8,001
+7,763
| +3,262% | +$57.7K | ﹤0.01% | 1731 |
|
|
2019
Q2 | $2K | Buy |
+238
| New | +$2.03K | ﹤0.01% | 3324 |
|
|
2019
Q1 | – | Sell |
-8
| Closed | – | – | 4312 |
|
|
2018
Q4 | $0 | Buy |
+8
| New | +$96 | ﹤0.01% | 4401 |
|
|
2016
Q4 | – | Sell |
-528
| Closed | -$1K | – | 4446 |
|
|
2016
Q3 | $1K | Sell |
528
-200
| -27% | -$265 | ﹤0.01% | 3381 |
|
|
2016
Q2 | $1K | Sell |
728
-249
| -25% | -$328 | ﹤0.01% | 4227 |
|
|
2016
Q1 | $1K | Buy |
+977
| New | +$1.96K | ﹤0.01% | 3803 |
|
|
2015
Q4 | – | Sell |
-1,903
| Closed | -$11K | – | 5088 |
|
|
2015
Q3 | $11K | Buy |
1,903
+1,597
| +522% | +$10.3K | ﹤0.01% | 2247 |
|
|
2015
Q2 | $2K | Buy |
+306
| New | +$2.53K | ﹤0.01% | 3803 |
|
Other funds holding VKTX
VCM
VPM
Tower Research Capital (TRC)'s VKTX Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Viking Therapeutics (VKTX) stake by 3,177% in Q1 2026, buying an estimated $298K and bringing the position to 9,568 shares worth $311K. The position accounts for 0.01% of the portfolio, ranked #1282.
Tower Research Capital (TRC) first reported a position in VKTX in Q2 2015 and has held it in 34 quarters since. The position peaked at $1.09M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Tower Research Capital (TRC) held 9,568 shares of Viking Therapeutics worth $311K as of Q1 2026.
- Tower Research Capital (TRC) bought 9,276 Viking Therapeutics shares in Q1 2026, an estimated $298K.
- Viking Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1282 holding.
- Tower Research Capital (TRC) first reported a position in Viking Therapeutics in Q2 2015 and has held it in 34 quarters since.
- Tower Research Capital (TRC)'s Viking Therapeutics position peaked at $1.09M in Q2 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.